The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Open accessAbstract
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although the presence of an overt frontotemporal dementia syndrome can be defined on the basis of established criteria, there are no such criteria for the prodromal forms of fronto temporal lobar degeneration, except for progressive supranuclear See Online for appendix Review palsy.31”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [31]
In the citing paper
“Neuropathologically, PSP is defined by the accumulation of pTau in both neurons and glial cells.369”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [369]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Appelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,774
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Self-citationClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citationQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., Swieten, J. C. V., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,065
Progressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
Self-citation
Cited by
Sorted by citations
Items 201–300 of 486
Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
Karimi, N., Catak, F. B., Arslan, E. O., Saghazadeh, A., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109445 · Cited by 11
Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy
Simoes, F. A., Joilin, G., Peters, O., Schneider, L., Priller, J., Spruth, E. J., Vogt, I. R., Kimmich, O., Spottke, A. E., Hoffmann, D. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314554 · Cited by 10
Self-citationSerum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson’s Disease
Cristiani, C. M., Scaramuzzino, L., Quattrone, A., Parrotta, E. I., Cuda, G., & Quattrone, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136882 · Cited by 10
Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy
Rosina, M., Veltri, F., Nesci, V., Bissacco, J., Bovenzi, R., Mascioli, D., Simonetta, C., Zenuni, H., Maftei, D., Marano, M., et al. (2024) · Movement Disorders · doi:10.1002/mds.30009 · Cited by 10
Jellinger, K. A. (2025) · Diseases · doi:10.3390/diseases13020039 · Cited by 10
Ling, R., Cen, X., Wu, S., Wang, M., Zhang, Y., Jiang, J., Lu, J., Liu, Y., Zuo, C., Jiang, J., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1580910 · Cited by 10
Biobanking for Neurodegenerative Diseases: Challenge for Translational Research and Data Privacy
Giannella, E., Notarangelo, V., Motta, C., & Sancesario, G. M. (2021) · The Neuroscientist · doi:10.1177/10738584211036693 · Cited by 10
Lu, J., Clement, C., Hong, J., Wang, M., Li, X., Cavinato, L., Yen, T., Jiao, F., Wu, P., Wu, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107426 · Cited by 10
Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review
Macedo, A. C., Mariano, L. I., Martins, M. I., Friedlaender, C. V., Balbino, J. M. V., Rocha, J. V. D. F., Camargos, S., Cardoso, F., Caramelli, P., & de Souza, L. C. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13435 · Cited by 10
Strobel, J., Müller, H.-P., Ludolph, A. C., Beer, A. J., Sollmann, N., & Kassubek, J. (2023) · Cells · doi:10.3390/cells12242776 · Cited by 10
Poulidou, V., Liampas, I., Arnaoutoglou, M., Dardiotis, E., & Siokas, V. (2024) · Biomolecules · doi:10.3390/biom14101213 · Cited by 11
Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen‐Plotkin, A. S., Rosenthal, L. S., Dawson, T. M., Na, C. H., & Pantelyat, A. Y. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09507-3 · Cited by 10
Bârlescu, L. A., Müller, H., Uttner, I., Ludolph, A. C., Pinkhardt, E. H., Huppertz, H., & Kassubek, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.720634 · Cited by 9
Chang, J. Y., Rukavina, K., Lawn, T., & Chaudhuri, К. R. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2004108 · Cited by 10
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy
Ma, J., Dong, C., Qiao, H., Barret, O., Tamagnan, G. D., Mao, W., Xu, E., Zhang, C., Lu, J., Chan, P., et al. (2024) · Movement Disorders · doi:10.1002/mds.29769 · Cited by 9
Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy
Liu, F., Lu, J., Li, X., Ge, J., Sun, Y., Yen, T., Jiao, F., Chen, M., Zhao, J., Yao, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06923-3 · Cited by 9
Calogero, A. M., Viganò, M., Budelli, S., Galimberti, D., Fenoglio, C., Cartelli, D., Lazzari, L., Lehenkari, P. P., Canesi, M., Giordano, R., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13545 · Cited by 9
You, Y., Botros, M. B., Enoo, A. A. V., Bockmiller, A., Herron, S., Delpech, J.-C., & Ikezu, T. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.001 · Cited by 9
Progressive Supranuclear Palsy and Statin Use
Bayram, E., Marras, C., Standaert, D. G., Kluger, B. M., Bordelon, Y. M., Shprecher, D., & Litvan, I. (2020) · Movement Disorders · doi:10.1002/mds.28038 · Cited by 9
Self-citationPillas, D., Klein, A., Gasalla, T., Avberšek, A., Thompson, A., Wright, J., Mellor, J., & Scowcroft, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.821570 · Cited by 9
microRNA and circRNA in Parkinson’s Disease and atypical parkinsonian syndromes
Bougea, A. M., & Stefanis, L. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.03.002 · Cited by 9
Stepwise Functional Brain Architecture Correlates with Atrophy in Progressive Supranuclear Palsy
Spinelli, E. G., Ghirelli, A., Bottale, I., Basaia, S., Canu, E., Castelnovo, V., Volonté, M. A., Galantucci, S., Magnani, G., Caso, F., et al. (2024) · Movement Disorders · doi:10.1002/mds.29887 · Cited by 8
Kovács, G. G., Respondek, G., van Eimeren, T., Holler, E., Levin, J., Müller, U., Schwarz, S. C., Rösler, T. W., Schweyer, K., & Höglinger, G. U. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0584-3 · Cited by 8
Self-citationSchubert, E., Dogan, S., Dillmann, U., Schaefer-Schuler, A., Fassbender, K. C., Ezziddin, S., & Spiegel, J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.07.003 · Cited by 8
Slade, S. C., Bruce, C., McGinley, J. L., Bloem, B. R., & Morris, M. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234265 · Cited by 8
Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies
Frey, K. A. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.003 · Cited by 8
Dissecting parkinsonism: cognitive and gait disturbances
Tipton, P. W. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0084 · Cited by 10
Krishnan, S., George, S. S., Radhakrishnan, V., Raghavan, S., Thomas, B., Thulaseedharan, J. V., & Puthenveedu, D. K. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02352-5 · Cited by 8
Natural clinical course of progressive supranuclear palsy in Chinese patients in Hong Kong
Shea, Y., Shum, C., Lee, S., Chiu, P. K., Ks, L., Kwan, Y., Mok, F. C.-K., & Chan, F. H.-W. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj198101 · Cited by 8
on behalf of the BoProPark Study Group, Buonaura, G. C., Sambati, L., Baschieri, F., Vitiello, M., Contin, M., Tonon, C., Capellari, S., Provini, F., & Cortelli, P. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04305-9 · Cited by 8
Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism
Cerroni, R., Liguori, C., Stefani, A., Conti, M., Garasto, E., Pierantozzi, M., Mercuri, N. B., Bernardini, S., Fucci, G., & Massoud, R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00126 · Cited by 8
Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
Ishiguro, T., & Kasuga, K. (2024) · Brain Sciences · doi:10.3390/brainsci14090859 · Cited by 7
Pathomechanisms of depression in progressive supranuclear palsy
Jellinger, K. A. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02621-w · Cited by 7
Aberrant dynamic functional network connectivity in progressive supranuclear palsy
Qu, J., Tian, M., Zhu, R., Song, C., Wu, Y., Xu, G., Liu, Y., & Wang, D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106493 · Cited by 7
Xu, D., Zhu, W., Huo, L., Zhu, S., Li, F., & Wang, H. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.020 · Cited by 7
Eye Movement Recordings: Practical Applications in Neurology
Rizzo, J., Beheshti, M., Dai, W., & Rucker, J. C. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1698742 · Cited by 7
Craig, K. J., & Day, M. P. (2021) · Nursing · doi:10.1097/01.nurse.0000751340.92329.ae · Cited by 7
Machine Learning for Parkinson’s Disease and Related Disorders
Faouzi, J., Colliot, O., & Corvol, J. (2023) · Neuromethods · doi:10.1007/978-1-0716-3195-9_26 · Cited by 7
Jia, P., Zhang, J., Han, J., & Ji, Y. (2022) · Brain and Behavior · doi:10.1002/brb3.2827 · Cited by 7
Lim, S., Tan, A. H., Foo, J. N., Tan, Y. J., Chew, E. G. Y., Ahmad‐Annuar, A., Closas, A. M. F. D., Pajo, A. T., Lim, J. L., Tay, Y. W., et al. (2024) · Journal of Movement Disorders · doi:10.14802/jmd.24009 · Cited by 7
Picillo, M., Cuoco, S., Amboni, M., Bonifacio, F. P., Bruno, A., Bruschi, F., Cappiello, A., Micco, R. D., Rosa, A. D., Biasio, F. D., et al. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03944-x · Cited by 7
Single-cell atlas of progressive supranuclear palsy reveals a distinct hybrid glial cell populationPreprint
Sharma, A., Song, W.-M., Farrell, K., Whitney, K., Zhang, B., Crary, J., & Pereira, A. C. (2021) · bioRxiv · doi:10.1101/2021.04.11.439393 · Cited by 7
Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials
Marchand, F., Blaise, A.-S., Defebvre, L., Cailliau, É., Bombois, S., Devos, D., & Moreau, C. (2024) · Journal of Parkinson s Disease · doi:10.1177/1877718x241291996 · Cited by 6
Demleitner, A. F., Gomes, L. C., Wenz, L., Tzeplaeff, L., Pürner, D., Luib, E., Kunze, L. H., & Lingor, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05252-2 · Cited by 6
A novel MAPT variant (E342K) as a cause of familial progressive supranuclear palsy
Li, H., Li, Q., Weng, Q., Cui, R., Yen, T., & Li, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1372507 · Cited by 6
Is there a spinal tap responder in progressive supranuclear palsy? The first prospective study
Ohara, M., Hattori, T., Chen, Q., Shimano, K., Hirata, K., Matsui, M., & Yokota, T. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12391-4 · Cited by 6
Qu, J., Qu, Y., Zhu, R., Wu, Y., Xu, G., & Wang, D. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14901 · Cited by 6
Wang, H., Wang, B., Liao, Y., Niu, J., Chen, M., Chen, X., Dou, X., Yu, C., Zhong, Y., Wang, J., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06954-w · Cited by 7
Bakar, Z. H. A., Kato, T., Yanagisawa, D., Bellier, J., Mukaisho, K., & Tooyama, I. (2021) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.21-00019 · Cited by 6
Cognitive Syndromes Associated With Movement Disorders
Goldman, J. G., & Holden, S. K. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001134 · Cited by 6
PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy
Li, X., Chen, M., Liang, X., Yao, R., Shen, B., Wu, B., Li, G., Sun, Y., Wu, J.-J., Liu, F., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223553 · Cited by 6
Bessemer, R. A., Iansavitchene, A., Jenkins, M. E., Finger, E. C., & Gofton, T. E. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120614 · Cited by 6
Visual Search in Progressive Supranuclear Palsy
Smith, D. T., & Archibald, N. K. (2018) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_72 · Cited by 6
Emerging drugs for progressive supranuclear palsy
Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6
Berthier, M. L., Hoet, F., Beltrán‐Corbellini, Á., Santana-Moreno, D., Edelkraut, L., & Dávila, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.635896 · Cited by 7
Peelaerts, W., Brito, F., den Haute, C. V., Janer, A. B., Steiner, J. A., Brundin, P., & Baekelandt, V. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.012 · Cited by 7
A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC
García‐González, P., Lara, H. R., Compta, Y., Fernandez, M., van der Lee, S. J., de Rojas, I., Saiz-Aúz, L., Painous, C., Camara, A., Muñoz, E., et al. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-025-01872-3 · Cited by 9
Jaberi, K. R., Haghighi, M. R., Aligholi, H., Takallu, S., Asadi, P., Mirzaei, E., Jaberi, A. R., & Sahraian, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119622 · Cited by 6
Bernardo, M. D., Diana, F., Gioia, M., Luca, M. D., Tepedino, M. F., Pellecchia, M. T., Rosa, N., Barone, P., & Picillo, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206671 · Cited by 5
Hounie, A. G., & Vasques, M. A. A. (2019) · Medical Cannabis and Cannabinoids · doi:10.1159/000503864 · Cited by 5
Belgrado, E., Tereshko, Y., Tuniz, F., Lettieri, C., Bagatto, D., Fabbro, S., Piccolo, D., Gigli, G. L., Škrap, M., & Valente, M. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120536 · Cited by 5
The Role of MicroRNAs in Progressive Supranuclear Palsy—A Systematic Review
Ćwiklińska, A., Procyk, G., Koziorowski, D., & Szlufik, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158243 · Cited by 5
Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view
Jellinger, K. A. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02890-7 · Cited by 5
Does Midbrain Atrophy Distinguish Progressive Supranuclear Palsy from Frontotemporal Dementia?
Cunningham, M. C. Q. E. S., Camargos, S., Jeunon, V. R., Rocha, N. P., Teixeira, A. L., Maciel, T. D. O., Resende, E. D. P. F., Cardoso, F., Caramelli, P., & de Souza, L. C. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70058 · Cited by 5
Abnormal structural connectivity in progressive supranuclear palsy—Richardson syndrome
Prasad, S., Rajan, A., Pasha, S. A., Mangalore, S., Saini, J. S., Ingalhalikar, M., & Pal, P. K. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13372 · Cited by 5
Васенина, Е. Е., & Levin, O. S. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202012010222 · Cited by 5
The Application of Deep Brain Stimulation for Progressive Supranuclear Palsy: A Systematic Review
Wen, Y., Jiao, B., & Zhou, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.827472 · Cited by 5
Xie, D., Huang, H., Zhao, Q., Ning, P., Shen, Q., Lu, H., Xu, F., Fu, X., & Xu, Y. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06296-1 · Cited by 5
An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau
Beck, G., Yamashita, R., Kido, K., Ikenaka, K., Chiba, T., Yonenobu, Y., Saito, Y., Morii, E., Hasegawa, M., Murayama, S., et al. (2023) · Neuropathology · doi:10.1111/neup.12890 · Cited by 5
Cappiello, A., Abate, F., Adamo, S., Tepedino, M. F., Donisi, L., Ricciardi, C., Avallone, A. R., Caterino, M., Cuoco, S., Pellecchia, M. T., et al. (2024) · Movement Disorders · doi:10.1002/mds.29774 · Cited by 5
Lastri, D. N., & Alwahdy, A. S. (2020) · MNJ (Malang Neurology Journal) · doi:10.21776/ub.mnj.2020.006.01.10 · Cited by 5
Brain FDG-PET: clinical use in dementing neurodegenerative conditions
Nobili, F. M., Schmidt, R., Carrió, I., & Frisoni, G. B. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4027-y · Cited by 5
Cummings, L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108587921 · Cited by 4
Chen, T., Gong, T., Chen, Y., Yang, A., Zhao, C., Sun, Z., Zhao, Y., Zhou, L., Chen, W., Liu, Y., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107076 · Cited by 4
Lim, Y. Z., Ngim, S. J., Fernandiz, J. C., Closas, A. M. F. D., Toh, T. S., Anuar, A. N. K., Chang, E. S. W., Cheok, J. J. W., Tay, Y. W., Ding, H. X., et al. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108060 · Cited by 4
Benussi, A., & Vucic, S. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2025.2111459 · Cited by 4
Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework
Ryan, C. B., Camargo, C. J., Salan, T., Pallikkuth, S., Gao, H., & Govind, V. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13539-6 · Cited by 6
Markiewicz, M. G., Migda, B., Otto‐Ślusarczyk, D., Madetko‐Alster, N., Wiercińska‐Drapało, A., Darewicz, M., Struga, M., & Alster, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412122 · Cited by 4
Li, Q., Liu, H., Zhu, Q., Zhang, R., Liang, D., Zhang, J., Jin, R., Chen, Y., Qin, C., & Teng, J. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111046 · Cited by 4
Cook, S. E. V., Menšíková, K., Koníčková, D., Šlanhofová, H., Klíčová, K., Raška, M., Zapletalová, J., Friedecký, D., & Kaňovský, P. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02902-6 · Cited by 4
Verwaerde, P., & Defert, O. (2025) · ChemMedChem · doi:10.1002/cmdc.202400891 · Cited by 4
Comment on “Is it Useful to Classify PSP and CBD as Different Disorders?”
Lang, A. E. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12676 · Cited by 4
Self-citationHow can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
Lozupone, M., Dibello, V., Daniele, A., Solfrizzi, V., Resta, E., & Panza, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2345734 · Cited by 5
Circular walking is useful for assessing the risk of falls in early progressive supranuclear palsy
Ohara, M., Hirata, K., Matsubayashi, T., Chen, Q., Shimano, K., Hanazawa, R., Hirakawa, A., Yokota, T., & Hattori, T. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12551-6 · Cited by 4
Rapid Cognitive Deterioration in Progressive Supranuclear Palsy: A 1‐Year Follow‐Up Study
Li, X., Yang, Y., Jiao, F., Tang, G., Chen, M., Yao, R., Zhao, Y., Liang, X., Shen, B., Sun, Y., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14315 · Cited by 4
Lee, S., Kim, H., Kim, R., Jin, B., Kim, S.-Y., Woo, K.-A., Shin, J. H., Jeon, B., Kim, H., & Lee, J. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107301 · Cited by 4
Wang, M., Lu, J., Li, L., Liu, F., Jiao, F., Wu, P., Ge, J., Wang, L., Brendel, M., Rominger, A., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11440-4 · Cited by 4
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
Cuina, M. L., & Meissner, W. G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.010 · Cited by 4
Jimenez, H. T., Carrión, J., Adrien, L. R., Wolin, A., Eun, J. D., Cinamon, E., Chang, E. H., Davies, P., Vo, A., & Koppel, J. L. (2023) · Biomedicines · doi:10.3390/biomedicines11082091 · Cited by 4
The discriminative linguistic profiles of progressive supranuclear palsy and Parkinson's disease
Busteed, L., Horta‐Barba, A., Reig, A., García‐Sánchez, C., Pascual‐Sedano, B., Gich, I. J., Ciffone, P. R., Kulisevsky, J., & Pagonabarraga, J. (2024) · Neurología · doi:10.1016/j.nrl.2023.06.010 · Cited by 3
Dam, T., Yang, L., Gillis, C., Li, Y., O'Gorman, J. T., Kolb, B., Boxer, A. L., Golbe, L. I., Haeberlein, S. B., & On behalf of the AL-108-231, P. (2025) · Nature Communications · doi:10.1038/s41467-024-55442-0 · Cited by 3
Self-citationAnyfantakis, G., Manouvelou, S., Koutoulidis, V., Velonakis, G., Scarmeas, N., & Papageorgiou, S. G. (2025) · Biomedicines · doi:10.3390/biomedicines13051009 · Cited by 3
Lu, H., Ren, J., Hua, L., Xie, D., Zhao, Q., Huang, H., Ning, P., Shen, Q., Wang, H., Xu, F., et al. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106767 · Cited by 3
Self-assembled monolayers for bio-analytical SERS applications: from single to mixed component SAMs
Cheng, T., Li, C., Ye, Z., Ye, J., Bell, S. E. J., & Xu, Y. (2026) · Materials Horizons · doi:10.1039/d5mh02043c · Cited by 4
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank
Zhao, C. W., Dale, M. L., Pantelyat, A. Y., Tartaglia, M. C., Schneider, R. B., Coughlin, D. G., Rodriguez‐Porcel, F. E., Wszołek, Z. K., Xie, T., Golbe, L. I., et al. (2026) · Movement Disorders · doi:10.1002/mds.70287 · Cited by 3
Self-citationMartins, M. I., Cardoso, F., Caramelli, P., Mariano, L. I., Rocha, N. P., Jaeger, A., Teixeira, A. L., Tumas, V., Camargos, S., & de Souza, L. C. (2023) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acad081 · Cited by 3
Yamahara, N., Yoshikura, N., & Shimohata, T. (2024) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001920 · Cited by 3
A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
Kawabata, K., Krismer, F., Heim, B., Hussl, A., Mueller, C., Scherfler, C., Gizewski, E. R., Seppi, K., & Poewe, W. H. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13987 · Cited by 3
Kleinz, T., Scholz, L., Huckemann, S., Rohmann, R., Kuhn, E. M., Averdunk, P., Kools, S., Hilker, L., Bieber, A., Müller, K., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241267300 · Cited by 3
A new step towards targeting tau
Corvol, J., & Buée, L. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30161-9 · Cited by 3
Metadata
- Authors
- Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U.
- Affiliations
- University of California, San Francisco (US)
- Qingdao University (CN)
- Rutgers, The State University of New Jersey (US)
- University of California San Diego (US)
- University of Toronto (CA)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Boxer, Adam L
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 16
- Issue
- 7
- Pages
- 552-563
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5802400
- OpenAlex
- W2625168757
- Cited by
- 485
- References
- 105
- Citations by year
- 2026: 45 · 2025: 52 · 2024: 59 · 2023: 42 · 2022: 57 · 2021: 56 · 2020: 62 · 2019: 61 · 2018: 43 · 2017: 7
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (HO2402/6‐2)
- National Institutes of Health
- National Institute on Aging (P50AG005131, U01AG045390, R01AG038791, P01AG019724)
- National Heart, Lung, and Blood Institute (T35HL007491)
- National Institute of Neurological Disorders and Stroke (U01NS086659, U54NS092089)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- progressive supranuclear palsy, diagnostic criteria, tau pathology, 4-repeat tau, biomarkers, atypical parkinsonism, disease-modifying therapy, neurodegenerative diseases, Alzheimer's disease, chronic traumatic encephalopathy
- MeSH terms
- Humans, Supranuclear Palsy, Progressive, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
